- Home
- NVCR vs ZLAB Comparison
NVCR vs ZLAB Comparison
Compare NVCR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCR | ZLAB |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | Switzerland | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.0B |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NVCR | ZLAB |
|---|---|---|
| Price | $15.86 | $17.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $28.08 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 1.4M | 795.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.79 | ★ 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $655,353,000.00 | $460,156,000.00 |
| Revenue This Year | $7.72 | $9.75 |
| Revenue Next Year | $6.74 | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.28 | ★ 15.33 |
| 52 Week Low | $9.82 | $15.96 |
| 52 Week High | $19.25 | $44.34 |
Technical Indicators
Market Signals| Indicator | NVCR | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 33.89 |
| Support Level | $12.48 | $17.11 |
| Resistance Level | $18.80 | $19.64 |
| Average True Range (ATR) | 0.88 | 0.68 |
| MACD | -0.43 | -0.20 |
| Stochastic Oscillator | 22.59 | 16.20 |
Price Performance
Historical ComparisonAbout NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.